Calistoga Pharmaceuticals Presented Preclinical and Clinical Data on CAL-101
June 15, 2010
Calistoga Pharmaceuticals Inc., of Seattle, presented preclinical and clinical data on CAL-101, the company's oral, delta selective PI3K inhibitor. Results from the interim assessment of the ongoing Phase I trial showed clinical benefit in patients with relapsed or refractory indolent non-Hodgkin's lymphoma, mantle cell lymphoma and chronic lymphocytic leukemia. Preclinical results assessing selected chemokines in plasma and circulating CLL cells from patients in the Phase I study supported that CAL-101 inhibits chemokine signaling and production from CLL cells and the microenvironment, the company said.
